2026-04-17T05:35:27Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/58932025-10-24T10:19:09Zcom_2072_378070com_2072_378040col_2072_378092

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response Moreno, Christophe Sarrazin, Christoph Gschwantler, Michael Foster, Graham R. Craxi, Antonio Asselah, Tarik Buti Ferret, Maria Fetge - Malalties Medicaments - Administració DISEASES::Digestive System Diseases::Liver Diseases Other subheadings::Other subheadings::Other subheadings::/drug therapy ENFERMEDADES::enfermedades del sistema digestivo::enfermedades hepáticas Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia Esdeveniments adversos; Malalties del fetge; Teràpia amb inhibidors de la proteasa Eventos adversos; Las enfermedades del hígado; Terapia con inhibidores de proteasa Adverse events; Liver diseases; Protease inhibitor therapy Background HCV GT4 accounts for up to 20% of HCV infections worldwide. Simeprevir, given for 12 weeks as part of a 24- or 48-week combination regimen with PR is approved for the treatment of chronic HCV GT4 infection. Primary study objectives were assessment of efficacy and safety of simeprevir plus PR in treatment-naïve patients with HCV GT4 treated for 12 weeks. Primary efficacy outcome was sustained virologic response 12 weeks post-treatment (SVR12). Additional objectives included investigation of potential associations of rapid virologic response and baseline factors with SVR12. Methods This multicentre, open-label, single-arm study (NCT01846832) evaluated efficacy and safety of simeprevir plus PR in 67 patients with HCV GT4 infection. Patients were treatment-naïve, aged 18–70 years with METAVIR F0–F2 fibrosis. Patients with early virologic response (HCV RNA <25 IU/mL [detectable/undetectable in IL28B CC patients or undetectable in IL28B CT/TT patients] at Week 2 and undetectable at Weeks 4 and 8) were eligible to stop all treatment at the end of Week 12, otherwise PR therapy was continued to Week 24. Results Of 67 patients treated, 34 (51%) qualified for 12-week treatment including all but one patient with IL28B CC genotype (14/15). All patients in the 12-week group had undetectable HCV RNA at end of treatment, and 97% (33/34) achieved SVR12. No new safety signals with simeprevir plus PR were identified. The proportion of patients experiencing Grade 3–4 adverse events was lower in the 12-week group than in the 24-week group. Conclusions Our findings on simeprevir plus PR therapy shortened to 12 weeks in patients with HCV GT4 infection with favourable baseline characteristics and displaying early on-treatment virologic response are encouraging. No new safety signals were associated with simeprevir plus PR in this study. The study described in this manuscript (HPC3014; NCT01846832) was sponsored by Janssen Pharmaceuticals. The funder was involved in study design, data collection and analysis, decision to publish, and preparation of the manuscript. Editorial support was provided by Ian Grieve (Medical Writer at Zoetic Science, an Ashfield Company, part of UDG Healthcare plc, Macclesfield, UK); this support was funded by Janssen Pharmaceuticals. This does not alter our adherence to PLOS ONE policies on sharing data and materials. 2025-10-24T10:19:09Z 2025-10-24T10:19:09Z 2025-10-24T10:19:09Z 2021-04-22T07:54:10Z 2021-04-22T07:54:10Z 2017-01-05 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/5893 PLoS ONE;12(1) https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0168713 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Public Library of Science Scientia